| 11.10 07:34 | FDA gibt Roche-Brustkrebsmedikament Itovebi die Zulassung |
| 11.10 07:09 | dpa-AFX: *ROCHE: FDA APPROVES ITOVEBI FOR ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH PIK3CA MUTATION |
| 11.10 07:00 | Press Release: FDA approves Roche's Itovebi, a -2- |
| 11.10 07:00 | Press Release: FDA approves Roche's Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation |
| 11.10 05:15 | dpa-AFX: WDH/Roche-Krebsmittel Inavolisib erhält Zulassung in den USA |
| 11.10 03:05 | dpa-AFX: FDA Approves Genentech's Itovebi For Advanced Breast Cancer With PIK3CA Mutation |
| 10.10 22:36 | dpa-AFX: Roche-Krebsmittel Inavolisib erhält Zulassung in den USA |
| 10.10 13:34 | dpa-AFX: Tempest Inks Deal With Roche To Support Advancement Of Amezalpat Combination Therapy |
| 10.10 13:16 | dpa-AFX: *TEMPEST ENTERS DEAL WITH ROCHE TO SUPPORT ADVANCEMENT OF AMEZALPAT COMBINATION THERAPY INTO FIRST-LINE HCC PIVOTAL TRIAL |
| 10.10 07:47 | dpa-AFX: Roche's Companion Diagnostic Test, VENTANA CLDN18 (43-14A) RxDx Assay Gets CE Certification |
| 10.10 07:09 | dpa-AFX: *ROCHE: VENTANA? CLDN18 (43-14A) RXDX ASSAY GETS CE MARK APPROVAL FOR CLDN18 PROTEIN EXPRESSION IN TUMOURS OF PATIENTS WITH GASTRIC CANCER |
| 10.10 07:00 | Press Release: Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY |
| 09.10 17:51 | Aktien Schweiz schließen mit China-Hoffnungen freundlich |
| 04.10 17:40 | Aktien Schweiz knapp behauptet - US-Jobdaten dämpfen Zinshoffnungen |
| 03.10 17:39 | Aktien Schweiz schwächer - Sika am Kapitalmarkttag unter Druck |
| 03.10 07:57 | dpa-AFX: ANALYSE-FLASH: Goldman hebt Ziel für Roche auf 260 Franken - 'Sell' |
| 03.10 07:57 | dpa-AFX: Goldman hebt Ziel für Roche auf 260 Franken - 'Sell' |
| 03.10 07:19 | dpa-AFX: *GOLDMAN RAISES ROCHE PRICE TARGET TO 260 (250) SFR - 'SELL' |
| 03.10 07:19 | dpa-AFX: *GOLDMAN HEBT ZIEL FÜR ROCHE AUF 260 (250) CHF - 'SELL' |
| 02.10 17:39 | Aktien Schweiz etwas fester - Erholung von Vortagesverlusten |
|
|
